HCC: Metastatic: 2nd Line: Non-cirrhotic: Oncolytic immunotherapy: RP2-003

Study snapshot

Locally advanced unresectable, recurrent, and/or metastatic HCC
Must have progressed on 1st line therapy that contained anti-PD-1 or anti-PD-L1 therapy as their immediate prior treatment regimen
Child-Pugh A determined withint 14 days of first treatment
All patients must undergo EGD with esophageal varices assessment
Measurable and injectable disease
Must be willing to undergo biopsy
ECOG PS 0-1
No significant bleeding event in last 12 months
No macroscopic vascular invastion into major blood vessels
No rare HCC variants
No liver tumors that are estimated to invade more than one-third of the liver
No known acute or chronic HBV/HCV unless PCR below lower limits of detection
No known HIV
No known CNS metastatses